Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 11, 2018
- Accepted in final form January 11, 2019
- First Published April 10, 2019.
Article Versions
- Previous version (April 10, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Linda Kalilani, PhD,
- Edward Faught, MD,
- Hyunmi Kim, MD, PhD, MPH,
- Chakkarin Burudpakdee, PharmD,
- Arpamas Seetasith, PhD,
- Scott Laranjo, MBA,
- David Friesen, BSc,
- Kathrin Haeffs, PhD,
- Victor Kiri, PhD, MPH and
- David J. Thurman, MD, MPH
- Linda Kalilani, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
UCB Pharma, Real World Evidence Methodologist, 6 years
NONE
NONE
NONE
NONE
UCB Pharma
NONE
NONE
NONE
NONE
NONE
NONE
UCB Pharma, 6 years Stock/Stock Options, Medical Equipment & Materials: UCB Pharma, 6 years
NONE
NONE
- Edward Faught, MD,
1. Eisai Ltd. 2. SK Life Science 3. Sage pharmaceuticals 4. Biogen
NONE
1. Wake Forest University, honorarium for lectures 2. University of Nebraska, honorarium as visiting professor
Epilepsy Currents, contributing editor for clinical science, 2015-2021
NONE
NONE
NONE
Medscape
NONE
NONE
NONE
1. UCB Pharma 2. Brain Sentinel 3) Eisai Ltd
National Institutes of Health, 1RO1NS08098-01, consultant, 2013-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hyunmi Kim, MD, PhD, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I got a research support as a coinvestigator on research projects, which were funded by UCB Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chakkarin Burudpakdee, PharmD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity at IQVIA, a consulting research company for the past 4 years.
NONE
NONE
NONE
I am employed at IQVIA, a consultancy that received financial compensation for conducting and interpreting this analysis. No financial compensation has been provided for writing or reviewing this manuscript as a coauthor.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Arpamas Seetasith, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Seetasith works for IQVIA, a consulting firm which received consultancy fees from UCB Pharma to conduct the study.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Laranjo, MBA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I was a UCB employee from March 2014 to April 2018.
NONE
NONE
NONE
NONE
NONE
NONE
UCB, 3/2014 to 4/2018. Stock/Stock Options, Medical Equipment & Materials: Neurocrine Biosciences 2016 to present, Ultragenix 2017-2018
NONE
NONE
- David Friesen, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Haeffs, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
UCB Biosciences GmbH, RWE data analyst, 3 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Victor Kiri, PhD, MPH and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David J. Thurman, MD, MPH
NONE
NONE
NONE
Epilepsia, Editorial Board member, 2012-2017
NONE
NONE
Emory University School of Medicine, Adjunct Professor of Neurology
Consultant to UCB, Inc., 2013-2018
NONE
NONE
NONE
UCB, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From UCB Pharma (L.K.), Raleigh, NC; Department of Neurology (E.F., D.J.T.), Emory University School of Medicine, Atlanta, GA; Department of Neurology (H.K.), Stanford University School of Medicine, Palo Alto, CA; IQVIA (C.B., A.S.), Fairfax, VA; UCB Pharma (S.L.), Smyrna, GA; UCB Pharma (D.F.), Ascot, Berkshire, UK; UCB Pharma (K.H.), Monheim am Rhein, Germany; and FV & JK Consulting Ltd. (V.K.), Guildford, Surrey, UK. S.L. is currently employed by Aerie Pharmaceuticals, Durham, NC.
- Correspondence
Dr. Kalilani linda.kalilani{at}ucb.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Author response: Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US
- Linda Kalilani, Real World Evidence Methodologist, UCB Biosciences Inc.
- Edward Faught, Director of the Emory Epilepsy Center, Department of Neurology, Emory University School of Medicine (Atlanta)
- David J. Thurman, Adjunct Professor of Neurology, Department of Neurology, Emory University School of Medicine (Atlanta)
- Hyunmi Kim, Neurologist, Stanford University School of Medicine (Palo Alto, CA)
Submitted May 20, 2019 - Reader response: Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US
- Nitin K. Sethi, Associate Professor of Neurology, New York-Presbyterian Hospital, Weill Cornell Medical Center (New York, NY)
Submitted April 15, 2019
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.